13F filer · CIK 351051 ↗
Massachusetts Institute of Technology
You are looking at Q1 2019. See the latest, Q2 2026 →
Reported value
$117.6M
+0.5% on the quarter before
Positions
4
1 new · 4 sold out
Top 10
100.0%
of the value
Est. gain
+$13.3M
on stocks held all quarter
Est. return
+13.3%
on those stocks since Q4 2018
Positions as of Mar 31, 2019, from Massachusetts Institute of Technology's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2018. Striped tiles are options.
Largest buys
Since Q4 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Boston Omaha Corp~$3.5MAdded · 38.6% → 44.0%+138,328 shares
- Audentes Therapeutics Inc~$1.1MNew · 0.0% → 0.9%+27,931 shares
Largest sells
Since Q4 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Smartsheet Inc~$8.9MSold out · 7.6% → 0.0%−358,924 shares
- Jbg Smith Pptys~$7.1MCut · 51.2% → 54.4%−172,032 shares
- Beigene Ltd~$1.1MSold out · 0.9% → 0.0%−7,669 shares
- Ppdai Group Inc~$871,000Sold out · 0.7% → 0.0%−242,019 shares
- Carbon Black Inc~$355,000Sold out · 0.3% → 0.0%−26,772 shares
Holdings
As of Mar 31, 2019. Changes are in shares against Dec 31, 2018, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jbg Smith PptysCOM · shares −10.0% · price +18.8% | 54.4% | $64.0M | +$10.1M | ||||||||
| Boston Omaha CorpCOM · shares +7.2% · price +6.8% | 44.0% | $51.7M | +$3.1M | ||||||||
| Audentes Therapeutics IncCOM · shares New | 0.93% | $1.1M | — | ||||||||
| Textron IncCOM · shares 0% · price +10.2% | 0.69% | $811,000 | +$75,000 | ||||||||
| Total · 4 positions | 100% | $117.6M | +$13.3M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2018 to Q1 2019: 3 stocks held throughout, up $13.3M (+13.3%).
- Jbg Smith Pptys+$10.1M+19%
- Boston Omaha Corp+$3.1M+7%
- Textron Inc+$75,000+10%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | $732.6M+27% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $577.0M−23% | SEC ↗ |
| Q4 2025 | Feb 12, 2026 | $753.3M−18% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $920.4M−8% | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | $995.5M+41% | SEC ↗ |
| Q1 2025 | May 14, 2025 | $707.2M+0% | SEC ↗ |
| Q4 2024 | Feb 12, 2025 | $705.1M−6% | SEC ↗ |
| Q3 2024 | Nov 14, 2024 | $749.0M+17% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $638.9M+14% | SEC ↗ |
| Q1 2024 | May 14, 2024 | $558.2M+3% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $539.6M−7% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $581.2M−13% | SEC ↗ |
| Q2 2023 | Aug 14, 2023 | $669.2M+5% | SEC ↗ |
| Q1 2023 | May 4, 2023 | $639.6M+6% | SEC ↗ |
| Q4 2022 | Feb 10, 2023 | $602.4M+2% | SEC ↗ |
| Q3 2022 | Nov 3, 2022 | $588.0M+26% | SEC ↗ |
| Q2 2022 | Aug 12, 2022 | $466.3M−26% | SEC ↗ |
| Q1 2022 | May 13, 2022 | $626.9M−15% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $738.1M+727% | SEC ↗ |
| Q4 2020 | Feb 5, 2021 | $89.2M+98% | SEC ↗ |
| Q3 2020 | Nov 12, 2020 | $45.1M−34% | SEC ↗ |
| Q2 2020 | Aug 10, 2020 | $68.0M+52% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $44.8M−43% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $78.7M−16% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $94.2M−10% | SEC ↗ |
| Q2 2019 | Aug 9, 2019 | $104.4M−11% | SEC ↗ |
| Q1 2019 | May 14, 2019 | $117.6M+1% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $117.1M | SEC ↗ |